Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Philadelphia, Pennsylvania 19103


This phase I trial is studying the side effects and best dose of combination chemotherapy when given with radiation therapy in treating patients with stage III or stage IV endometrial cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.

Study summary:

OBJECTIVES: I. Determine the safety and maximum tolerated doses of paclitaxel and cisplatin when administered with radiotherapy in patients with stage III or IV endometrial cancer. II. Assess the time to disease progression and overall survival of patients treated with this regimen. OUTLINE: This is a dose-escalation study of paclitaxel and cisplatin. Patients receive paclitaxel IV over 1 hour and cisplatin IV on days 1, 8, 15, 22, 29, and 36. Patients also undergo whole abdominal radiotherapy for 5 consecutive days weekly for 6 weeks. Cohorts of 3-6 patients receive escalating doses of paclitaxel and cisplatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are treated at that dose level. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter. PROJECTED ACCRUAL: A total of 3-48 patients will be accrued for part I and 14-20 patients will be accrued for part II of this study.


Inclusion Criteria: - Histologically confirmed surgical stage III or IV endometrial cancer - Any stage clear or serous papillary endometrial cancer - Positive para-aortic lymph nodes allowed - Tumor must be surgically reduced to 2 cm or less within 8 weeks of study - Must have had hysterectomy and bilateral salpingo-oophorectomy - No recurrent disease - No metastases to lung or liver parenchyma or inguinal or scalene lymph nodes - Performance status - GOG 0-2 - Absolute neutrophil count greater than 2,000/mm^3 - Platelet count at least 100,000/mm^3 - Bilirubin no greater than 1.5 times upper limit of normal (ULN) - SGOT no greater than 3 times ULN - Creatinine no greater than 1.5 times ULN - No other prior or concurrent malignancy in the past 5 years except non-melanoma skin cancer - No prior chemotherapy - No prior radiotherapy - See Disease Characteristics - No more than 8 weeks since prior surgery - No prior anticancer therapy that would preclude study



Primary Contact:

Principal Investigator
D. McMeekin
Gynecologic Oncology Group

Backup Contact:


Location Contact:

Philadelphia, Pennsylvania 19103
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.